## Neil R Poulter

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5407431/publications.pdf

Version: 2024-02-01

211 papers

32,517 citations

<sup>38742</sup> 50 h-index

175 g-index

216 all docs

216 docs citations

216 times ranked

27860 citing authors

#	Article	IF	CITATIONS
1	Improving the Management of Hypertension by Tackling Awareness, Adherence, and Clinical Inertia: A Symposium Report. American Journal of Cardiovascular Drugs, 2022, 22, 251-261.	2.2	10
2	Effects of glucose and blood pressure reduction on subclinical cardiac damage: Results from ADVANCE. International Journal of Cardiology, 2022, 358, 103-109.	1.7	2
3	Global Impact of Different Blood Pressure Thresholds in 4 021 690 Participants of the May Measurement Month Initiative. Hypertension, 2022, 79, 1497-1505.	2.7	4
4	Hypertension in stroke survivors and associations with national premature stroke mortality: data for 2A·5 million participants from multinational screening campaigns. The Lancet Global Health, 2022, 10, e1141-e1149.	6.3	10
5	Additive association of knowledge and awareness on control of hypertension: a cross sectional survey in rural India. Journal of Hypertension, 2021, 39, 44-45.	0.5	1
6	May Measurement Month 2019: results of blood pressure screening from 47 countries. European Heart Journal Supplements, 2021, 23, B1-B5.	0.1	13
7	May Measurement Month 2019: an analysis of blood pressure screening results from Jamaica. European Heart Journal Supplements, 2021, 23, B82-B85.	0.1	0
8	May Measurement Month 2019: an analysis of blood pressure screening results from Ulaanbaatar, Mongolia. European Heart Journal Supplements, 2021, 23, B107-B109.	0.1	0
9	May Measurement Month 2019: an analysis of blood pressure screening results from Slovenia. European Heart Journal Supplements, 2021, 23, B131-B133.	0.1	3
10	May Measurement Month 2019: an analysis of blood pressure screening results from Kenya. European Heart Journal Supplements, 2021, 23, B86-B88.	0.1	1
11	May Measurement Month 2019: an analysis of blood pressure screening results from Venezuela, Latin America. European Heart Journal Supplements, 2021, 23, B151-B153.	0.1	0
12	May Measurement Month 2019: an analysis of blood pressure screening results from Ghana-Sub-Saharan Africa. European Heart Journal Supplements, 2021, 23, B62-B65.	0.1	2
13	May Measurement Month 2019: blood pressure screening results from Chile. European Heart Journal Supplements, 2021, 23, B40-B42.	0.1	0
14	May Measurement Month 2019: an analysis of blood pressure screening results from South Africa. European Heart Journal Supplements, 2021, 23, B134-B137.	0.1	2
15	May Measurement Month 2019: an analysis of blood pressure screening results from Cameroon. European Heart Journal Supplements, 2021, 23, B33-B36.	0.1	5
16	May Measurement Month 2019: an analysis of blood pressure screening results from Angola. European Heart Journal Supplements, 2021, 23, B9-B11.	0.1	1
17	Blood pressure screening results from May Measurement Month 2019 in Vietnam. European Heart Journal Supplements, 2021, 23, B154-B157.	0.1	3
18	May Measurement Month 2019: an analysis of blood pressure screening results from Ecuador. European Heart Journal Supplements, 2021, 23, B55-B58.	0.1	1

#	Article	IF	CITATIONS
19	May Measurement Month 2019: an analysis of blood pressure screening results from Nigeria. European Heart Journal Supplements, 2021, 23, B114-B116.	0.1	2
20	May Measurement Month 2019: an analysis of blood pressure screening results from Botswana. European Heart Journal Supplements, 2021, 23, B27-B29.	0.1	0
21	May Measurement Month 2019: an analysis of blood pressure screening results from Saudi Arabia. European Heart Journal Supplements, 2021, 23, B128-B130.	0.1	5
22	May Measurement Month 2019: an analysis of blood pressure screening results from Colombia. European Heart Journal Supplements, 2021, 23, B46-B48.	0.1	2
23	May Measurement Month 2019: an analysis of blood pressure screening results from Korea. European Heart Journal Supplements, 2021, 23, B89-B91.	0.1	3
24	May Measurement Month 2019: an analysis of blood pressure screening results from the Democratic Republic of the Congo. European Heart Journal Supplements, 2021, 23, B52-B54.	0.1	1
25	May Measurement Month 2019: an analysis of blood pressure screening results from Bangladesh. European Heart Journal Supplements, 2021, 23, B21-B23.	0.1	1
26	May Measurement Month 2019: an analysis of blood pressure screening results from Malaysia. European Heart Journal Supplements, 2021, 23, B98-B100.	0.1	0
27	May Measurement Month 2019: an analysis of blood pressure screening results from Mexico. European Heart Journal Supplements, 2021, 23, B104-B106.	0.1	2
28	May Measurement Month 2019: an analysis of blood pressure screening results from Taiwan. European Heart Journal Supplements, 2021, 23, B141-B143.	0.1	0
29	May Measurement Month 2019: an analysis of blood pressure screening results from Hungary. European Heart Journal Supplements, 2021, 23, B70-B72.	0.1	2
30	May Measurement Month 2019: an analysis of blood pressure screening results from Republic of the Congo. European Heart Journal Supplements, 2021, 23, B49-B51.	0.1	1
31	May Measurement Month 2019: an analysis of blood pressure screening results from Mauritius. European Heart Journal Supplements, 2021, 23, B101-B103.	0.1	0
32	Variation in hypertension clinical practice guidelines: a global comparison. BMC Medicine, 2021, 19, 117.	5.5	19
33	May Measurement Month 2019: an analysis of blood pressure screening results from Tunisia. European Heart Journal Supplements, 2021, 23, B144-B146.	0.1	1
34	May Measurement Month 2019: an analysis of blood pressure screening results from Lebanon. European Heart Journal Supplements, 2021, 23, B92-B94.	0.1	3
35	May Measurement Month 2019: an analysis of blood pressure screening results from Spain. European Heart Journal Supplements, 2021, 23, B138-B140.	0.1	3
36	May Measurement Month 2019: an analysis of blood pressure screening results from Zambia. European Heart Journal Supplements, 2021, 23, B158-B160.	0.1	1

3

#	Article	IF	CITATIONS
37	May Measurement Month 2019: an analysis of blood pressure screening results from Armenia. European Heart Journal Supplements, 2021, 23, B15-B17.	0.1	O
38	May Measurement Month 2019: an analysis of blood pressure screening results from Malawi. European Heart Journal Supplements, 2021, 23, B95-B97.	0.1	1
39	May Measurement Month 2019: an analysis of blood pressure screening results from Cape Verde. European Heart Journal Supplements, 2021, 23, B37-B39.	0.1	1
40	May Measurement Month 2019: an analysis of blood pressure screening results in the Philippines. European Heart Journal Supplements, 2021, 23, B120-B123.	0.1	1
41	May Measurement Month 2019: an analysis of blood pressure screening results from China. European Heart Journal Supplements, 2021, 23, B43-B45.	0.1	3
42	May Measurement Month 2019: an analysis of blood pressure screening results from Albania. European Heart Journal Supplements, 2021, 23, B6-B8.	0.1	0
43	May Measurement Month 2019: an analysis of blood pressure screening results from Italy. European Heart Journal Supplements, 2021, 23, B77-B81.	0.1	4
44	May Measurement Month 2019: an analysis of blood pressure screening results from Benin–Sub-Saharan Africa. European Heart Journal Supplements, 2021, 23, B24-B26.	0.1	0
45	May Measurement Month 2019: an analysis of blood pressure screening results from the United Kingdom and Republic of Ireland. European Heart Journal Supplements, 2021, 23, B147-B150.	0.1	2
46	May Measurement Month 2019: an analysis of blood pressure screening results from Australia. European Heart Journal Supplements, 2021, 23, B18-B20.	0.1	3
47	May Measurement Month 2019: blood pressure screening results in Georgia, Europe. European Heart Journal Supplements, 2021, 23, B59-B61.	0.1	0
48	May Measurement Month 2019: an analysis of blood pressure screening results from Brazil. European Heart Journal Supplements, 2021, 23, B30-B32.	0.1	1
49	May Measurement Month 2019: an analysis of blood pressure screening results from Poland. European Heart Journal Supplements, 2021, 23, B124-B127.	0.1	2
50	May Measurement Month 2019: an analysis of blood pressure screening results from Argentina. European Heart Journal Supplements, 2021, 23, B12-B14.	0.1	1
51	High prevalence of non-dipping patterns among Black Africans with uncontrolled hypertension: a secondary analysis of the CREOLE trial. BMC Cardiovascular Disorders, 2021, 21, 254.	1.7	9
52	May Measurement Month 2019: an analysis of blood pressure screening results from India. European Heart Journal Supplements, 2021, 23, B73-B76.	0.1	1
53	Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control. Diabetologia, 2021, 64, 2012-2025.	6.3	24
54	The factors influencing clinician use of hypertension guidelines in different resource settings: a qualitative study investigating clinicians' perspectives and experiences. BMC Health Services Research, 2021, 21, 767.	2.2	2

#	Article	IF	Citations
55	World Heart Federation Roadmap for Hypertension – A 2021 Update. Global Heart, 2021, 16, 63.	2.3	56
56	Prevalence of high blood pressure and cardiovascular risk factors from a community screening programme in the Middle-East; a 3-year analysis of data from the May Measurement Month programme (2017–2019) in Oman. Journal of Human Hypertension, 2021, , .	2.2	1
57	The power of genetic diversity in genome-wide association studies of lipids. Nature, 2021, 600, 675-679.	27.8	353
58	Medication adherence in hypertension. Journal of Hypertension, 2020, 38, 579-587.	0.5	55
59	May Measurement Month 2018: an analysis of blood pressure screening results from Nepal. European Heart Journal Supplements, 2020, 22, H92-H95.	0.1	5
60	May Measurement Month 2018: an analysis of blood pressure screening in Libya. European Heart Journal Supplements, 2020, 22, H77-H79.	0.1	0
61	May Measurement Month 2018: results of blood pressure screening from 41 countries. European Heart Journal Supplements, 2020, 22, H1-H4.	0.1	5
62	May Measurement Month 2018: an analysis of blood pressure screening results from Albania. European Heart Journal Supplements, 2020, 22, H5-H7.	0.1	2
63	May Measurement Month 2018: an analysis of blood pressure screening results from Angola. European Heart Journal Supplements, 2020, 22, H8-H10.	0.1	2
64	May Measurement Month 2018: an analysis of blood pressure screening results from Argentinean cohort. European Heart Journal Supplements, 2020, 22, H11-H13.	0.1	2
65	An analysis of blood pressure screening of 21Â112 participants in Armenia: May Measurement Month 2018. European Heart Journal Supplements, 2020, 22, H14-H16.	0.1	1
66	May Measurement Month 2018: an analysis of blood pressure screening results from Australia. European Heart Journal Supplements, 2020, 22, H17-H19.	0.1	4
67	May Measurement Month 2018: an analysis of blood pressure screening results from Botswana. European Heart Journal Supplements, 2020, 22, H23-H25.	0.1	2
68	May Measurement Month 2018: an analysis of blood pressure screening results from Chile. European Heart Journal Supplements, 2020, 22, H37-H39.	0.1	1
69	May Measurement Month 2018: an analysis of blood pressure screening results from China. European Heart Journal Supplements, 2020, 22, H40-H42.	0.1	6
70	May Measurement Month 2018: an analysis of blood pressure screening results from Republic of the Congo. European Heart Journal Supplements, 2020, 22, H47-H49.	0.1	4
71	Analysis of blood pressure and selected cardiovascular risk factors in the Democratic Republic of the Congo: the May Measurement Month 2018 results. European Heart Journal Supplements, 2020, 22, H50-H52.	0.1	3
72	May Measurement Month 2018: an analysis of blood pressure screening results in Georgia. European Heart Journal Supplements, 2020, 22, H56-H58.	0.1	1

#	Article	IF	CITATIONS
73	May Measurement Month 2018: an analysis of blood pressure screening results from Ghana. European Heart Journal Supplements, 2020, 22, H59-H61.	0.1	6
74	May Measurement Month 2018: an analysis of blood pressure screening campaign results in India. European Heart Journal Supplements, 2020, 22, H62-H65.	0.1	2
75	May Measurement Month 2018: an analysis of blood pressure screening results from Italy. European Heart Journal Supplements, 2020, 22, H70-H73.	0.1	4
76	May Measurement Month 2018: an analysis of blood pressure screening from Kenya. European Heart Journal Supplements, 2020, 22, H74-H76.	0.1	1
77	May Measurement Month 2018: an analysis of blood pressure screening results from Malawi. European Heart Journal Supplements, 2020, 22, H80-H82.	0.1	2
78	May Measurement Month 2018: an analysis of blood pressure screening results from Malaysia. European Heart Journal Supplements, 2020, 22, H83-H85.	0.1	4
79	May Measurement Month 2018: an analysis of blood pressure screening results from Oman. European Heart Journal Supplements, 2020, 22, H100-H103.	0.1	2
80	May Measurement Month 2018: an analysis of blood pressure screening in the Philippines. European Heart Journal Supplements, 2020, 22, H104-H107.	0.1	3
81	May Measurement Month 2018: an analysis of blood pressure screening campaign results from Poland. European Heart Journal Supplements, 2020, 22, H108-H111.	0.1	4
82	May Measurement Month 2018: an analysis of blood pressure screening results from Slovenia. European Heart Journal Supplements, 2020, 22, H112-H114.	0.1	1
83	May Measurement Month 2018: an analysis of blood pressure screening results from Sudan. European Heart Journal Supplements, 2020, 22, H122-H124.	0.1	3
84	May Measurement Month 2018: an analysis of blood pressure screening results from United Arab Emirates. European Heart Journal Supplements, 2020, 22, H128-H131.	0.1	3
85	Results of May Measurement Month 2018 campaign in Venezuela. European Heart Journal Supplements, 2020, 22, H135-H138.	0.1	1
86	May Measurement Month 2018: an analysis of blood pressure screening results from Vietnam. European Heart Journal Supplements, 2020, 22, H139-H141.	0.1	4
87	May Measurement Month 2018: an analysis of blood pressure screening results from Brazil. European Heart Journal Supplements, 2020, 22, H26-H29.	0.1	1
88	May Measurement Month 2018: an analysis of blood pressure screening results from Spain. European Heart Journal Supplements, 2020, 22, H119-H121.	0.1	5
89	May Measurement Month 2018: an analysis of blood pressure screening results from Nigeria. European Heart Journal Supplements, 2020, 22, H96-H99.	0.1	2
90	May Measurement Month 2018: an analyses of blood pressure screening results from Cabo Verde. European Heart Journal Supplements, 2020, 22, H30-H32.	0.1	2

#	Article	IF	CITATIONS
91	May Measurement Month 2018: an analysis of blood pressure screening results from Colombia. European Heart Journal Supplements, 2020, 22, H43-H46.	0.1	2
92	May Measurement Month 2018: an analysis of blood pressure screening results from Indonesia. European Heart Journal Supplements, 2020, 22, H66-H69.	0.1	4
93	May Measurement Month 2018: an analysis of blood pressure screening results from Mexico. European Heart Journal Supplements, 2020, 22, H89-H91.	0.1	2
94	May Measurement Month 2018: an analysis of blood pressure screening results in South Africa. European Heart Journal Supplements, 2020, 22, H115-H118.	0.1	1
95	May Measurement Month 2018: an analysis of blood pressure screening results from the UK and the Republic of Ireland. European Heart Journal Supplements, 2020, 22, H132-H134.	0.1	1
96	May Measurement Month 2018: an analysis of blood pressure screening results from Bangladesh. European Heart Journal Supplements, 2020, 22, H20-H22.	0.1	2
97	May Measurement Month 2018: an analysis of blood pressure screening results from Taiwan. European Heart Journal Supplements, 2020, 22, H125-H127.	0.1	3
98	May Measurement Month 2018: blood pressure screening results in Cameroon. European Heart Journal Supplements, 2020, 22, H33-H36.	0.1	2
99	Risk factors for kidney disorders in patients with type 2 diabetes at high cardiovascular risk: An exploratory analysis (DEVOTE 12). Diabetes and Vascular Disease Research, 2020, 17, 147916412097093.	2.0	6
100	Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial. Diabetes Care, 2020, 43, 1546-1552.	8.6	92
101	May Measurement Month 2019. Hypertension, 2020, 76, 333-341.	2.7	157
102	2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension, 2020, 75, 1334-1357.	2.7	1,895
103	May measurement month 2017: Latin America. Journal of Hypertension, 2020, 38, 1183-1188.	0.5	13
104	2020 International Society of Hypertension global hypertension practice guidelines. Journal of Hypertension, 2020, 38, 982-1004.	0.5	452
105	Plasma fatty acids and the risk of vascular disease and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE study. Diabetologia, 2020, 63, 1637-1647.	6.3	16
106	Effects of Liraglutide on CardiovascularÂOutcomes in Patients With Diabetes With or Without HeartÂFailure. Journal of the American College of Cardiology, 2020, 75, 1128-1141.	2.8	53
107	Potassium Intake in India: Opportunity for Mitigating Risks of High-Sodium Diets. American Journal of Preventive Medicine, 2020, 58, 302-312.	3.0	6
108	Chronotherapy in hypertension: the devil is in the details. European Heart Journal, 2020, 41, 1606-1607.	2.2	18

#	Article	IF	CITATIONS
109	Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 465-473.	4.5	32
110	A collaborative model for capacity building of primary care physicians in the management of Hypertension in India. Journal of Human Hypertension, 2019, 33, 562-565.	2.2	5
111	Effectiveness of twoâ€drug therapy versus monotherapy as initial regimen in hypertension: A propensity scoreâ€matched cohort study in the UK Clinical Practice Research Datalink. Pharmacoepidemiology and Drug Safety, 2019, 28, 1572-1582.	1.9	14
112	Multiancestry Genome-Wide Association Study of Lipid Levels Incorporating Gene-Alcohol Interactions. American Journal of Epidemiology, 2019, 188, 1033-1054.	3.4	85
113	May Measurement Month 2017: an analysis of blood pressure screening in the Philippines—South-East Asia and Australasia. European Heart Journal Supplements, 2019, 21, D92-D96.	0.1	5
114	May Measurement Month 2017: an analysis of blood pressure screening results in Georgia—Europe. European Heart Journal Supplements, 2019, 21, D53-D55.	0.1	2
115	Results of the May Measurement Month 2017: blood pressure campaign in Venezuela—Americas. European Heart Journal Supplements, 2019, 21, D124-D126.	0.1	3
116	Do we know more about hypertension in Poland after the May Measurement Month 2017?—Europe. European Heart Journal Supplements, 2019, 21, D97-D100.	0.1	6
117	May Measurement Month 2017: an analysis of blood pressure screening results in Austria—Europe. European Heart Journal Supplements, 2019, 21, D17-D20.	0.1	3
118	May Measurement Month 2017: an analysis of blood pressure screening results in China—East Asia. European Heart Journal Supplements, 2019, 21, D37-D39.	0.1	10
119	May Measurement Month 2017: Blood pressure screening results from Zambia—Sub-Saharan Africa. European Heart Journal Supplements, 2019, 21, D130-D132.	0.1	6
120	May Measurement Month 2017: analysis of the blood pressure screening results in Argentinaâ€"Americas. European Heart Journal Supplements, 2019, 21, D8-D10.	0.1	5
121	May Measurement Month 2017: an analysis of blood pressure screening results in Armenia—Europe. European Heart Journal Supplements, 2019, 21, D11-D13.	0.1	3
122	May Measurement Month 2017: an analysis of blood pressure screening in Hungaryâ€"Europe. European Heart Journal Supplements, 2019, 21, D56-D58.	0.1	2
123	May Measurement Month 2017: Results of 39 national blood pressure screening programmes. European Heart Journal Supplements, 2019, 21, D1-D4.	0.1	13
124	May Measurement Month 2017: the results of blood pressure screening of 14Â845 individuals in Kenyaâ€"Sub-Saharan Africa. European Heart Journal Supplements, 2019, 21, D71-D73.	0.1	7
125	May Measurement Month 2017: an analysis of blood pressure screening results in Nepal—South Asia. European Heart Journal Supplements, 2019, 21, D83-D85.	0.1	7
126	May Measurement Month 2017: screening for hypertension in Nigeriaâ€"Sub-Saharan Africa. European Heart Journal Supplements, 2019, 21, D86-D88.	0.1	4

#	Article	IF	CITATIONS
127	Rates of untreated, treated, and controlled hypertension and relationships between blood pressure with other cardiovascular risk factors in Brazzaville (Republic of the Congo): May Measurement Month 2017—Sub-Saharan Africa. European Heart Journal Supplements, 2019, 21, D44-D46.	0.1	5
128	May Measurement Month 2017: an analysis of the blood pressure screening campaign results in Indonesiaâ€"South-East Asia and Australasia. European Heart Journal Supplements, 2019, 21, D63-D65.	0.1	4
129	May Measurement Month 2017: results of a blood pressure screening campaign in Malawiâ€"Sub-Saharan Africa. European Heart Journal Supplements, 2019, 21, D74-D76.	0.1	5
130	May Measurement Month 2017: an analysis of blood pressure screening results from the United Kingdom and the Republic of Ireland—Europe. European Heart Journal Supplements, 2019, 21, D121-D123.	0.1	7
131	May Measurement Month 2017: an analysis of blood pressure screening results from the United Arab Emirates—Northern Africa and Middle East. European Heart Journal Supplements, 2019, 21, D118-D120.	0.1	7
132	May Measurement Month 2017 in Chileâ€"Americas. European Heart Journal Supplements, 2019, 21, D34-D36.	0.1	4
133	May Measurement Month 2017: an analysis of blood pressure screening in Angola—Sub–Saharan Africa. European Heart Journal Supplements, 2019, 21, D5-D7.	0.1	4
134	May Measurement Month 2017: an analysis of blood pressure screening results from Australia—South-East Asia and Australasia. European Heart Journal Supplements, 2019, 21, D14-D16.	0.1	6
135	May Measurement Month 2017 blood pressure screening: findings from Malaysia—South-East Asia and Australasia. European Heart Journal Supplements, 2019, 21, D77-D79.	0.1	20
136	May Measurement Month 2017 in Russia: hypertension treatment and control—Europe. European Heart Journal Supplements, 2019, 21, D101-D103.	0.1	6
137	May Measurement Month 2017: an analysis of blood pressure screening in Spain—Europe. European Heart Journal Supplements, 2019, 21, D107-D110.	0.1	3
138	May Measurement Month (MMM) 2017: an analysis of blood pressure screening results in Bangladeshâ€"South Asia. European Heart Journal Supplements, 2019, 21, D21-D24.	0.1	3
139	MMM17-Cameroon, analysis and opportunities—Sub-Saharan Africa. European Heart Journal Supplements, 2019, 21, D31-D33.	0.1	10
140	May Measurement Month 2017: an analysis of blood pressure screening results in Colombia—Americas. European Heart Journal Supplements, 2019, 21, D40-D43.	0.1	4
141	May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension. European Heart Journal, 2019, 40, 2006-2017.	2.2	193
142	May Measurement Month 2017: Brazilian resultsâ€"Americas. European Heart Journal Supplements, 2019, 21, D25-D27.	0.1	6
143	Comparison of Dual Therapies for Lowering Blood Pressure in Black Africans. New England Journal of Medicine, 2019, 380, 2429-2439.	27.0	85
144	Efficacy and Safety of Incremental Dosing of a New Single-Pill Formulation of Perindopril and Amlodipine in the Management of Hypertension. American Journal of Cardiovascular Drugs, 2019, 19, 313-323.	2.2	9

#	Article	IF	Citations
145	Multi-ancestry genome-wide gene–smoking interaction study of 387,272 individuals identifies new loci associated with serum lipids. Nature Genetics, 2019, 51, 636-648.	21.4	112
146	Clinical characteristics, antihypertensive medication use and blood pressure control among patients with treatment-resistant hypertension. Journal of Hypertension, 2019, 37, 2216-2224.	0.5	7
147	May Measurement Month 2017: an analysis of blood pressure screening results in South Africa-Sub-Saharan Africa. European Heart Journal Supplements, 2019, 21, D104-D106.	0.1	3
148	Rationale and design of the comparison of 3 combination therapies in lowering blood pressure in black Africans (CREOLE study): 2 $\tilde{A}$ — 3 factorial randomized single-blind multicenter trial. American Heart Journal, 2018, 202, 5-12.	2.7	9
149	Hypertension. Nature Reviews Disease Primers, 2018, 4, 18014.	30.5	636
150	Cardiovascular, respiratory, and related disorders: key messages from Disease Control Priorities, 3rd edition. Lancet, The, 2018, 391, 1224-1236.	13.7	101
151	Randomized Crossover Trial of the Impact of Morning or Evening Dosing of Antihypertensive Agents on 24-Hour Ambulatory Blood Pressure. Hypertension, 2018, 72, 870-873.	2.7	54
152	Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nature Genetics, 2018, 50, 1412-1425.	21.4	924
153	May Measurement Month 2017: an analysis of blood pressure screening results worldwide. The Lancet Global Health, 2018, 6, e736-e743.	6.3	245
154	Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease. Circulation, 2018, 137, 2179-2183.	1.6	80
155	Are the American Heart Association/American College of Cardiology High Blood Pressure Guidelines Fit for Global Purpose?: Thoughts From the International Society of Hypertension. Hypertension, 2018, 72, 260-262.	2.7	20
156	Blood pressure measurement in special populations and circumstances. Journal of Clinical Hypertension, 2018, 20, 1122-1127.	2.0	20
157	Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial. Lancet, The, 2018, 392, 1127-1137.	13.7	87
158	Novel genetic associations for blood pressure identified via gene-alcohol interaction in up to 570K individuals across multiple ancestries. PLoS ONE, 2018, 13, e0198166.	2.5	94
159	Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. Nature Genetics, 2017, 49, 403-415.	21.4	492
160	Discovery of novel heart rate-associated loci using the Exome Chip. Human Molecular Genetics, 2017, 26, 2346-2363.	2.9	29
161	May Measurement Month: a global blood pressure screening campaign. Lancet, The, 2017, 389, 1678-1680.	13.7	25
162	May Measurement Month. Journal of Hypertension, 2017, 35, 1126-1128.	0.5	21

#	Article	IF	Citations
163	Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. New England Journal of Medicine, 2017, 377, 723-732.	27.0	480
164	Prognostic Impact of Inâ€Hospital and Postdischarge Heart Failure in Patients With Acute Myocardial Infarction: A Nationwide Analysis Using Data From the Cardiovascular Disease in Norway (CVDNOR) Project. Journal of the American Heart Association, 2017, 6, .	3.7	25
165	Liraglutide and Renal Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2017, 377, 839-848.	27.0	903
166	Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2017, 377, 1228-1239.	27.0	1,455
167	Cancer risks of anti-hyperglycemic drugs for type 2 diabetes treatment $\hat{a} \in \hat{a}$ a clinical appraisal. Journal of Diabetes and Its Complications, 2017, 31, 1451-1457.	2.3	3
168	Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients. Clinical Research in Cardiology, 2017, 106, 58-68.	3.3	23
169	An evaluation of the effect of an angiotensin-converting enzyme inhibitor on the growth rate of small abdominal aortic aneurysms: a randomized placebo-controlled trial (AARDVARK). European Heart Journal, 2016, 37, 3213-3221.	2.2	80
170	Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 213-221.	2.2	12
171	Is It Time to Reappraise Blood Pressure Thresholds and Targets?. Hypertension, 2016, 68, 266-268.	2.7	16
172	Plasma Lipidomic Profiles Improve on Traditional Risk Factors for the Prediction of Cardiovascular Events in Type 2 Diabetes Mellitus. Circulation, 2016, 134, 1637-1650.	1.6	205
173	Changes in Quality of Life Associated with Complications of Diabetes: Results from the ADVANCE Study. Value in Health, 2016, 19, 36-41.	0.3	83
174	The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax) Tj ETQqC	01 <b>0</b> 9rgBT	/0 <b>4e</b> rlock 10
175	An evaluation of the effect of an angiotensin-converting enzyme inhibitor on the growth rate of small abdominal aortic aneurysms: a randomised placebo-controlled trial (AARDVARK). Health Technology Assessment, 2016, 20, 1-180.	2.8	19
176	Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet, The, 2015, 385, 2264-2271.	13.7	564
177	Hypertension. Lancet, The, 2015, 386, 801-812.	13.7	539
178	Reducing Cardiovascular Mortality Through Prevention and Management of Raised Blood Pressure: A World Heart Federation Roadmap. Global Heart, 2015, 10, 111.	2.3	104
179	Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes. Diabetologia, 2014, 57, 2465-2474.	6.3	346
180	Impact of Visit-to-Visit Glycemic Variability on the Risks of Macrovascular and Microvascular Events and All-Cause Mortality in Type 2 Diabetes: The ADVANCE Trial. Diabetes Care, 2014, 37, 2359-2365.	8.6	284

#	Article	IF	CITATIONS
181	Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes. New England Journal of Medicine, 2014, 371, 1392-1406.	27.0	520
182	Do Cardiac Biomarkers NT-proBNP and hsTnT Predict Microvascular Events in Patients With Type 2 Diabetes? Results From the ADVANCE Trial. Diabetes Care, 2014, 37, 2202-2210.	8.6	32
183	Hypertension management in England: a serial cross-sectional study from 1994 to 2011. Lancet, The, 2014, 383, 1912-1919.	13.7	226
184	Commentary: Shaper and Jones, 'Serum-cholesterol, diet and coronary heart-disease in Africans and Asians in Uganda': 50-year-old findings only need interpretational fine tuning to come up to speed!. International Journal of Epidemiology, 2012, 41, 1228-1230.	1.9	2
185	Impact of amlodipine-based therapy among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trialâ^'Blood Pressure Lowering Arm (ASCOT-BPLA). Journal of Hypertension, 2011, 29, 583-591.	0.5	32
186	A new dimension in hypertension management with the amlodipine/perindopril combination. Journal of Hypertension, 2011, 29, S15-S21.	0.5	3
187	Effects of $\hat{l}^2$ blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurology, The, 2010, 9, 469-480.	10.2	634
188	Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet, The, 2010, 375, 895-905.	13.7	1,525
189	Compliance, Safety, and Effectiveness of Fixed-Dose Combinations of Antihypertensive Agents. Hypertension, 2010, 55, 399-407.	2.7	579
190	Continued Improvement in Hypertension Management in England. Hypertension, 2009, 53, 480-486.	2.7	190
191	Combined Effects of Routine Blood Pressure Lowering and Intensive Glucose Control on Macrovascular and Microvascular Outcomes in Patients With Type 2 Diabetes. Diabetes Care, 2009, 32, 2068-2074.	8.6	230
192	Albuminuria and Kidney Function Independently Predict Cardiovascular and Renal Outcomes in Diabetes. Journal of the American Society of Nephrology: JASN, 2009, 20, 1813-1821.	6.1	787
193	Coronary heart disease benefits from blood pressure and lipid-lowering. International Journal of Cardiology, 2009, 135, 218-222.	1.7	9
194	Baseline Heart Rate, Antihypertensive Treatment, and Prevention of Cardiovascular Outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). Journal of the American College of Cardiology, 2009, 54, 1154-1161.	2.8	63
195	Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension. Journal of Hypertension, 2009, 27, 947-954.	0.5	30
196	Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE. Journal of Hypertension, 2009, 27, S3-S8.	0.5	25
197	Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 2008, 358, 2560-2572.	27.0	6,447
198	The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. Journal of Hypertension, 2008, 26, 2103-2111.	0.5	98

#	Article	IF	CITATIONS
199	Effect of Spironolactone on Blood Pressure in Subjects With Resistant Hypertension. Hypertension, 2007, 49, 839-845.	2.7	583
200	Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. European Heart Journal, 2006, 27, 2982-2988.	2.2	146
201	Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. The. 2005. 366. 895-906.	13.7	2,662
202	Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet, The, 2005, 366, 907-913.	13.7	314
203	Measures of Global Risk: Old Versus New Methods. Clinical and Experimental Hypertension, 2004, 26, 653-662.	1.3	1
204	Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients who have Average or Lower-than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial???Lipid Lowering Arm (ASCOT-LLA). Drugs, 2004, 64, 43-60.	10.9	189
205	Hypertension Treatment and Control in Five European Countries, Canada, and the United States. Hypertension, 2004, 43, 10-17.	2.7	944
206	Past, present, and future clinical trials of cardiovascular risk reductionâ€"the hyperlipidemia perspective. International Congress Series, 2004, 1262, 265-268.	0.2	1
207	Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trialâ€"Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet, The. 2003. 361. 1149-1158.	13.7	3,420
208	Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. Journal of Hypertension, 2001, 19, 1139-1147.	0.5	234
209	Association Between Smoking and Blood Pressure. Hypertension, 2001, 37, 187-193.	2.7	348
210	Ethnic Differences in the Hypertensive Heart and 24-Hour Blood Pressure Profile. Hypertension, 1998, 31, 1190-1194.	2.7	57
211	Psycho-Emotional Stress and Salt Intake May Interact to Raise Blood Pressure. European Journal of Cardiovascular Prevention and Rehabilitation, 1994, 1, 45-51.	2.8	7